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Introduction
The 2004 Expedition Inspiration Symposium was held
February 2004 in Sun Valley, Idaho and entitled ‘Breast
Cancer – The Development and Validation of New
Therapeutics’. In this consensus statement we will
summarize some of the key issues which we believe have
an impact on the rate of delivery of new therapeutics to
the clinic.
This summary will be in three parts: a brief overview
of the meeting, a discussion of issues which impact
generally on the development of new therapeutics for
cancer and finally detailed abstracts of the meeting with
key references on the subject matter of each. By way of
introduction it is worth pointing out that the pace of
basic and translational research underpinning new
clinical initiatives is astounding. New technologies, new
targets and new drugs are being developed at an ever
increasing rate. At the same time the incidence and
prevalence of breast cancer both continue to increase
internationally. It is therefore all the more critical to see
that every possible avenue to accelerate the pace at
which this science can be reduced to practice is pursued.
This was the paramount goal at the meeting.
Overview of the meeting
Laura Van’t Veer, PhD opened the meeting with an
update of the prognostic index that Netherlands Cancer
Institute has developed using micro array profiling
based on an analysis of thousands of expressed genes.
They have been able to identify and categorize patients
who appear either at sufficiently low risk of relapse to
forego further therapy or to be at relatively higher risk
of relapse (though not necessarily certain to benefit from
more aggressive therapy). This is now being prospec-
tively explored in two European trials.
Arul Chinnaiyan, MD, PhD, of the University of
Michigan presented data on ‘oncomine.org’ a tool which
he and colleagues have developed to provide the basis
for meta-analyses of micro array studies. This versatile
tool permits multiple comparisons amongst published
studies including ‘gene’ (one gene many data sets)
‘study’ (one data set many genes). This provides a un-
ique platform for cross validation across competing
analytic platforms and the potential to develop even
more discriminative gene sets for patient sub setting.
Kent Osborne, MD, of Baylor Breast Center focused
his talk on the diverse pathways by which estrogens
acting on estrogen receptors can affect tumor growth.
The increasing complexity of this system involving (at
least) two receptor genes, new multiple sites of cellular
localization, has created a myriad of new potential sites
for therapeutic modulation. This is further complicated
by an expanding group of ligands with differing speci-
ficites as well as a plastic milieu of co-activators and
repressors.
James Rae, PhD of the University of Michigan and
David Flockhart, MD, PhD of Indiana University re-
viewed the complexity posed to therapeutics by the
rapidly expanding field of pharmacogenomics. Eighty
five percentage of all drugs including most therapies
used for breast cancer require metabolic activation of
metabolism which is regulated by enzymes which are
variable in their activity. This variability is largely con-
trolled by inheritance of expressed allelles of differing
functionality. Drugs such as SERM’s, taxanes and an-
timetabolites are profoundly affected by these pathways
and furthermore there is considerable opportunity for
induction (or repression) of metabolic activity by co-
administered substances such as glucocorticoids.
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Max Wicha, MD of the University of Michigan
presented updated information on his long-standing
collaboration with Michael Clarke, MD and other col-
leagues in which they have succeeded in identifying a
miniscule sub population of cells from both normal and
malignant breast tissue which appear to meet criteria for
stem cells in that they have asymmetric mitosis giving
rise to progenitor cells as well as more differentiated cell
populations. The obvious implication of this work is
that therapies which effectively treat the majority of
tumor cells but ‘miss’ the stem cell population will fail
while therapies directed at stem cells can potentially
eradicate tumors. A corollary is that if stem cells are
<1% of tumors then array analyses, etc. may fail to
reveal properties of the most critical cells making up a
cancer.
George Sledge, Jr, MD also from the University of
Indiana, reviewed current progress in anti angiogenic
approaches particularly those directed against VEGF.
These clinical trials clearly requires better intermediate
end points to monitor effects of novel agents on either
vasculogenesis or blood flow. The redundancy of
angiogenic mechanisms may imply that such therapies
will have to be used at earlier points in tumor therapy –
a goal of the current trial of beracizamab and taxol in
metastatic breast cancer is now nearing its accrual tar-
get.
Michael Press, MND, PhD of USC Norris Com-
prehensive Cancer Center reviewed results of trast-
uzumab trials with a particular emphasis on the
absolutely essential need to adequately quantify HER-2/
neu over expression. There is clearly a substantial under
estimation of effectiveness of trastuzumab therapy be-
cause many patients have been mis classified as over
expressers on the basis of incorrect immuno histo-
chemical assays. Best use of targeted therapies will
obviously require accurate identification of the target
plus evidence for modulation of the target by the ther-
apeutic.
Clifford Hudis, MD of Memorial Sloan-Kettering
Cancer Center reviewed the biologic basis that cyclo-
oxygenase – 2 (cox-2) plays a role in human tumor
progression. These studies have provided a basis for
clinical trials of potent cox-2 inhibitors such as celec-
oxib. Because there are data that patients who over
express HER-2/neu also over express cox-2, he outlined
a trial in which patients whose tumors progress on
trastuzumab with or without chemotherapy continued
on that therapy but had celecoxib added to the regime.
This study was negative but because the data with aro-
matase inhibitors in HER-2/neu over expressors appear
so compelling, MA-27 C the intergroup trial comparing
exemestane to anastrozole has a follow on randomiza-
tion after 5 years to 3 more years of celecoxib versus
placebo. He also raised the interesting notion with so
many people on cox-2 inhibitors for non-malignant
disease that a massive public health experiment may be
underway testing the role of cox-2 in malignant pro-
gression.
Chris Benz, MD of the Buck Institute for Age Re-
search spoke about the potential role of proteasomal
degradation and inhibitors of this pathway as potential
targets for breast cancer therapy. Using an NCI library
of compounds with a substantial degree of structural
diversity, he was able to identify both a proteasome
inhibitor and a histone deacetylase inhibitor which were
able to turn off the HER2 promoter and by this means
lower expression of HER2/neu. These studies are early
but may lead to novel approaches to targeting HER2-
positive breast cancers.
Adrian Harris, MD, PhD from Oxford, England
discussed pharmacodynamic end points for phase I/II
trials. He raised the very interesting issue that response
rates even for established agents may appear to be
unacceptably low, by failing to interact with the target.
He explored topoisomerase IIa which is the target of
epipodophyllotoxin (VP-16) and showed that there was
a remarkable variation in response rate of patients based
upon expression of the target. Similarly, he presented
data on COMET assays for DNA strand breaks, as well
as assays of other control points for metalloproteinase
inhibitors and anti angiogenic agents. All of these data
have as their unifying principle the notion that it is
critical to measure surrogate endpoints and validate that
the therapeutic approach being attempted is interacting
with the target.
Finally, Marc Lippman, MD of the University of
Michigan presented data on new small molecule inhib-
itors of apoptosis. A near universal property of breast
cancer is the over expression of anti-apoptotic molecules
such as BCL-2 and BCL-XL. Together with his collab-
orators they have identified several small molecules
which can block the hetero dimerization of pro-apop-
totic molecules such as BAX or BAD with BCL- or
BCL- XL. By blocking this hetero dimerization breast
cancer cells appear to be sensitized to chemotherapeutic
agents and radiation treatment. One of these molecules
will soon be entering clinical trials.
Consensus issues
A series of issues were discussed which were felt to have
a substantial impact on the rapidity with which many
new therapeutic approaches could be brought to clinical
reality. Many of these issues could potentially be ad-
dressed and could result in speedier development of new
therapeutics.
Slow accrual to and diminishing support for clinical
trials has been a major impediment to the direct devel-
opment of new therapeutics. In Great Britain, the Na-
tional Health Service developed resources for
supporting a network of clinical trials which led from a
2% to a 10% rate of accrual of patients with breast
cancer on to clinical trials. In the United States funding
to the cooperative groups has remained flat and cancer
centers haven’t sufficient resources to independently
support the infrastructure necessary to conduct clinical
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trials. In addition, there have been substantial issues
with providing support for correlative studies of science.
As a result, many agents are not being developed as
effectively because of the failure to concurrently study
target validation. In fact, the FDA has not supported
target-based protocols as compared with disease-based
trials. Clearly there is need for a new paradigm in which
both industry and the FDA need to consider processes
by which drug trials aimed at specific targets can be
explored across disease types. In real dollars support for
clinical trials has, therefore, declined as a result of
inflation. Similarly, because of many bureaucratic issues
in handling multiple IRB’s and approval processes,
many pharmaceutical companies have taken drug trials
off-shore. An overhaul of IRB mechanisms is long
overdue.
Yet another presumably inadvertent outcome of the
Health Insurance Portability and Accountability Act
(HIPAA) has been the very great difficulty of not only
retrospective analyses of tumors but also prospective
analyses. The combination of HIPAA and IRB regula-
tions has crippled research on correlative science. Given
the widespread ability now to perform both protein and
RNA analyses on both previous frozen and paraffin
embedded materials it is exceedingly unfortunate that
much of this material remains un-explored in clinical
trials because of the inability to obtain appropriate
consents. Re-interpretation or re-writing of this legisla-
tion is required to assure adequate clinical materials for
retrospective analysis whilst assuring appropriate pa-
tient confidentiality.
Over and over again we have seen agents with
remarkable pre-clinical potency fail in the clinic because
of apparently inadequate response rates. However, it
should be recalled that were trastuzumab to have been
used in un-selected breast cancer patients the response
rates would have been 5% or less. Therefore there is a
critical need for appropriate validation of targets.
Clearly the drug must have a specific molecular target.
That target must be measurable in a clinically relevant
situation. The target must be biologically important and
finally it must be modulated by the therapy resulting in
clinical benefit.
For all these reasons and more, participants in the
symposium developed a series of recommendations
which we believe are worth significant discussion.
(I) Correlative studies accompanying large scale trials
of biological agents should be strongly encouraged. At
the FDA level, registration trials should potentially re-
quire prospective selection of relevant clinical materials
for correlative studies which should be made available
for independent investigators. There should be agree-
ment on appropriate consent forms at the time of surgery
which can allow clinical and biological information to be
harvested in such a fashion so as to protect patient pri-
vacy, but none the less allow appropriate correlative
studies to be done at a later time. Funds should be
supplied to the cooperative groups so that appropriate
correlative sciences studies can accompany clinical trials
in an efficient manner.
(II) IRB mechanisms need to be reformed potentially
at a national level. The processes of redundant bureau-
cratic issues have become so burdensome that clinicians
are discouraged from participating in clinical trials.
Pharmaceutical companies are discouraged from pur-
suing these trials. Academic teaching centers and clinical
research in general is being slowed. Attention needs to
be given at the national level to reform this process to
not only insure continued patient safety, but to provide
efficient mechanisms whereby trials can be proposed and
incorporated into the clinical management plans at
multiple centers.
(III) It is clear that the protection of intellectual
property has inhibited both academic and industrial
development of agents. Individual academic institu-
tions rarely have the technical expertise to rapidly de-
velop, protect, and license intellectual property. One
possibility is to consider a multi-institution consortium
to both protect intellectual property and do drug
development. By adding value to potential therapeutics
by bringing them to clinical trial substantial value can
be added and this could potentially speed up drug
development. At the present time there appear to be
few federal mechanisms for funding this kind of drug
development as the RO1 mechanism is both cumber-
some and rarely suitable for research which is some-
what less hypothesis-driven.
(IV) Additional funding is needed to provide for re-
search aimed at developing better methods for validat-
ing molecular targets and the interaction of drugs with
those targets. There has been minimal cross-platform
validation of technologies and unfortunately almost no
effort to fund tumor acquisition fixation or storage such
that materials can be used at a later date for multiple
institutions.
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